CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Preferred Stock	Common Stock	Additional Paid-In Capital	Treasury Stock	Retained Earnings (Deficit)	Accumulated Other Comprehensive Income	Total
Beginning Balance, Amount at Dec. 31, 2012	$ 0	$ 289	$ 58,614	$ (3,772)	$ 20,433	$ 2,975	$ 78,539
Beginning Balance, Shares at Dec. 31, 2012	0	28,876
Net proceeds from issuance of restricted stock, Amount	$ 0	$ 1	1,535	0	0	0	1,536
Net proceeds from issuance of restricted stock, Shares		66
Compensation expense on share-based awards	0	$ 0	513	0	0	0	513
Issuance of stock options for services from non-employees	0	0	548	0	0	0	548
Income tax benefit on share-based awards	0	0	(147)	0	0	0	(147)
Net proceeds from sale of shares, Amount	$ 0	$ 2	421	(229)	0	0	194
Net proceeds from sale of shares, Shares	0	163
Issuance of common stock in connection with the Somaxon acquisition, Amount	$ 0	$ 36	23,804	0	0	0	23,840
Issuance of common stock in connection with the Somaxon acquisition, Shares	0	3,658
Reclass of shares (previously subject to the put right of the former Cypress shareholders in connection with the Cypress acquisition) from temporary equity, Amount	$ 0	$ 44	34,266	0	0	0	34,310
Reclass of shares (previously subject to the put right of the former Cypress shareholders in connection with the Cypress acquisition) from temporary equity, Shares	0	4,427
Net loss	$ 0	$ 0	0	0	(25,635)	0	(25,635)
Unrealized gain on securities, net	0	0	0	0	0	(2,975)	(2,975)
Ending Balance, Amount at Dec. 31, 2013		$ 372	119,554	(4,001)	(5,202)	0	110,723
Ending Balance, Shares at Dec. 31, 2013		37,190
Net proceeds from issuance of restricted stock, Amount	$ 0	$ 2	(2)	(1,109)	0	0	(1,109)
Net proceeds from issuance of restricted stock, Shares	0	325
Compensation expense on share-based awards	$ 0	$ 0	4,686	0	0	0	4,686
Issuance of stock options for services from non-employees	0	0	119	0	0	0	119
Cancellation of ParaPRO stock options in connection with termination of contract	0	0	(1,294)	0	0	0	(1,294)
Income tax benefit on share-based awards	0	0	404	0	0	0	404
Issuance of warrants in connection with the acquisition of Treximet	0	0	2,359	0	0	0	2,359
Issuance of warrants in connection with the issuance of the February 2014 Convertible Notes, net	0	0	689	0	0	0	689
Net proceeds from sale of shares, Amount	$ 0	$ 9	2,613	(321)	0	0	2,301
Net proceeds from sale of shares, Shares	0	826
Net loss	$ 0	$ 0	0	0	(35,286)	0	(35,286)
Ending Balance, Amount at Dec. 31, 2014		$ 383	129,128	(5,431)	(40,488)	0	83,592
Ending Balance, Shares at Dec. 31, 2014		38,341
Net proceeds from issuance of restricted stock, Amount	$ 0	$ 0	0	(117)	0	0	(117)
Net proceeds from issuance of restricted stock, Shares	0	49
Compensation expense on share-based awards	$ 0	$ 0	5,944	0	0	0	5,944
Conversion of 8.0% convertible notes, Amount	$ 0	$ 181	59,991	0	0	0	60,172
Conversion of 8.0% convertible notes, Shares	0	18,056
Issuance of stock for inducment, Amount	$ 0	$ 23	19,477	0	0	0	19,500
Issuance of stock for inducment, Shares	0	2,338
Stock issued in connection with the purchase of Zohydro ER, Amount	$ 0	$ 17	11,909	0	0	0	11,926
Stock issued in connection with the purchase of Zohydro ER, Shares	0	1,682
Net proceeds from sale of shares, Amount	$ 0	$ 7	388	0	0	0	395
Net proceeds from sale of shares, Shares	0	647
Net loss	$ 0	$ 0	0	0	(148,315)	0	(148,315)
Ending Balance, Amount at Dec. 31, 2015	$ 0	$ 611	$ 226,837	$ (5,548)	$ (188,803)	$ 0	$ 33,097
Ending Balance, Shares at Dec. 31, 2015	0	61,113